Protagonist Therapeutics (PTGX) Competitors $44.99 -0.83 (-1.81%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$47.16 +2.18 (+4.83%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. ASND, MRNA, VTRS, QGEN, ROIV, LNTH, RVMD, BBIO, LEGN, and TGTXShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Ascendis Pharma A/S (NASDAQ:ASND) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends. Which has higher earnings and valuation, ASND or PTGX? Protagonist Therapeutics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$363.64M28.08-$409.12M-$7.10-23.59Protagonist Therapeutics$434.43M6.36-$78.96M$4.2010.71 Does the MarketBeat Community favor ASND or PTGX? Ascendis Pharma A/S received 157 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.87% of users gave Ascendis Pharma A/S an outperform vote while only 61.65% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformAscendis Pharma A/SOutperform Votes44866.87% Underperform Votes22233.13% Protagonist TherapeuticsOutperform Votes29161.65% Underperform Votes18138.35% Do institutionals and insiders believe in ASND or PTGX? 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ASND or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Ascendis Pharma A/S's net margin of -104.54%. Protagonist Therapeutics' return on equity of 34.68% beat Ascendis Pharma A/S's return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-104.54% N/A -39.23% Protagonist Therapeutics 52.76%34.68%30.98% Does the media favor ASND or PTGX? In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.42 beat Ascendis Pharma A/S's score of 1.07 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ASND or PTGX? Ascendis Pharma A/S presently has a consensus price target of $204.67, indicating a potential upside of 22.21%. Protagonist Therapeutics has a consensus price target of $65.44, indicating a potential upside of 45.46%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, ASND or PTGX? Ascendis Pharma A/S has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. SummaryProtagonist Therapeutics beats Ascendis Pharma A/S on 13 of the 19 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.76B$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio16.917.3222.5118.54Price / Sales6.36241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book7.706.486.734.25Net Income-$78.96M$143.41M$3.22B$248.18M7 Day Performance1.12%2.58%1.38%1.03%1 Month Performance-6.66%5.00%2.79%2.70%1 Year Performance76.16%-3.72%15.41%4.05% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics3.4684 of 5 stars$44.99-1.8%$65.44+45.5%+76.0%$2.76B$434.43M16.91120Upcoming EarningsNews CoveragePositive NewsASNDAscendis Pharma A/S2.3081 of 5 stars$161.15-2.4%$204.67+27.0%+18.8%$9.83B$363.64M-22.70640News CoverageMRNAModerna4.3466 of 5 stars$25.13+1.7%$58.70+133.6%-75.7%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.6837 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.8104 of 5 stars$40.51-0.5%$47.83+18.1%+1.4%$9.01B$1.98B112.806,030Upcoming EarningsROIVRoivant Sciences2.1942 of 5 stars$10.04-1.1%$17.50+74.3%+3.3%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9716 of 5 stars$100.62-0.7%$129.43+28.6%+57.2%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.7504 of 5 stars$36.56-0.5%$66.67+82.3%+4.7%$6.80B$742,000.00-10.18250Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5565 of 5 stars$33.51-1.1%$53.00+58.2%+42.1%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLEGNLegend Biotech2.6714 of 5 stars$32.24-1.7%$79.00+145.0%-22.8%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.3092 of 5 stars$36.97-3.5%$40.67+10.0%+185.7%$5.81B$329.00M-369.66290Upcoming EarningsPositive News Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Roivant Sciences Alternatives Lantheus Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
